Insmed Incorporated (INSM) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Insmed Inc (INSM) 3-Minute Overview > **💡 One-Sentence Summary** > > Simply put, Insmed is a biotech company that already has real drug revenue and fast growth, but the stock is still being valued like a pipeline success story—so execution on launches matters a lot. > **📍 Basic Profile** > > Market Cap **$23.0 billion** · Biotechnology · NASDAQ NMS - GLOBAL MARKET · Price **$106.24** > **⚡ 3 Things You Should Know** > > 1. 💰 Real sales, not just a science project: Q1 2026 revenue reached **$306.0 million**, with BRINSUPRI at **$207.9 million** and ARIKAYCE at **$98.1 million**. That matters because Insmed is no longer a pure “hope stock”—commercial execution is now the main driver. > > 2. ⚠️ Growth is strong, but profits are still deeply negative: the company’s **gross margin is excellent at 81.81%**, yet **net margin is -144.44%**. In other words, the drugs look economically attractive, but Insmed is still spending heavily to build and expand, so investors are paying for future scale rather than current earnings. > > 3. 📉 The market has cooled off fast: the stock is down sharply from its **52-week high of $212.75** to **$106.24**, and analysts have recently cut targets amid competitive concerns. What's interesting is that sentiment has weakened much faster than the business revenue trend, which means this has become more of an execution-confidence story than a simple momentum trade. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | Net margin -144.44%, still loss-making despite high gross margin | > | Growth Rate | Fast🚀 | 3-year revenue CAGR 35.2% | > | Financial Health | Healthy💚 | Current ratio 4.47, liquidity looks solid | > | Valuation | Pricey | No PE; PS 28.10x and PB 50.23x | ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Insmed develops and sells specialty biotech therapies, making money by commercializing rare-disease drugs to patients through the healthcare system. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | BRINSUPRI | 68.0% | ↑ | Now the main growth engine; Q1 2026 sales were $207.9m and up 44% sequentially | | ARIKAYCE | 32.0% | → | Still an important base business, contributing $98.1m in Q1 2026 | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 81.81% | Top tier | Very strong unit economics; biotech drug pricing power is clearly there | | Net Margin | -144.44% | Below Average | Commercial and R&D spending still overwhelms revenue | | ROE | -130.11% | Below Average | Not meaningful as a quality signal yet because the company remains loss-making | --- #### 📈 How's the Growth? **Growth Assessment:** High Growth | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | [Data unavailable] | [Data unavailable] | Strong multi-year growth | | Profit Growth | [Data unavailable] | [Data unavailable] | Losses remain significant | **Growth Quality:** > The growth looks more credible than many biotech stories because it is being driven by actual product sales, especially BRINSUPRI, rather than one-time licensing or accounting noise. The catch is that this growth still needs to prove it can translate into operating leverage, because right now revenue is scaling faster than before, but profits are still far away. --- #### 💰 Financial Health Check **One Sentence:** Think of it like someone with a lot of cash in the bank and strong income potential, but still spending aggressively to build a business that hasn’t reached break-even yet. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 98.5% | <60% safe | ⚠️High | | Current Ratio | 4.47 | >1.5 healthy | ✅Safe | | Cash Flow | -$5.17/share | >0 | 🚨Negative | Worth noting: liquidity is good, but the business is still burning cash. The shelf offering filing also suggests management wants financing flexibility, which is common in biotech—but can mean dilution risk if losses persist. --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $64.85 - 52-Week High: $212.75 - Current: $106.24, In the lower half of the range | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | ●(28% position) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | [Data unavailable] | 5-year avg [Data unavailable] | [Data unavailable] | | vs Peers | PS 28.10x | Industry avg [Data unavailable] | [Data unavailable] | **What the Current Valuation is Betting On:** > Basically, the market is still betting that BRINSUPRI can become a major franchise, ARIKAYCE can hold up as a revenue base, and the broader pipeline can justify biotech-style upside. But after the recent pullback, investors are clearly less willing to pay peak optimism multiples without cleaner proof on launch durability and competition. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-05-07 | Q1 2026 results: revenue hit $306.0m, with BRINSUPRI at $207.9m and ARIKAYCE at $98.1m | Positive — launch revenue looks strong and supports the commercial thesis | | 2026-05-13 / 2026-05-20 | Truist lowered target price to $185 from $205, citing competitive pressures | Negative — analysts still like the stock, but expectations are being trimmed | | 2026-05-14 | Mixed shelf offering filed | Negative — adds potential dilution overhang | | 2026-05-16 | CEO defended BRINSUPRI launch trajectory amid concerns over discontinuation rates | Neutral — management is pushing back, but this highlights a real issue the market is watching | ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 81.81% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | -144.44% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | -130.11% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | ↑ | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2026-03-31 | -$0.98 | -$0.76 | +22.34% Beat 😀 | | 2025-12-31 | -$1.32 | -$1.54 | -16.99% Miss 😟 | | 2025-09-30 | -$1.37 | -$1.75 | -28.09% Miss 😟 | | 2025-06-30 | -$1.32 | -$1.70 | -28.87% Miss 😟 | **Earnings Trend Interpretation:** One good quarter helped, but the broader pattern is still messy: Insmed missed estimates in the prior three quarters before the latest beat. In other words, the business may be improving operationally, but it has not yet earned a “consistently under-promising and over-delivering” reputation. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 27 firms | 96.4% | | Hold | 1 firm | 3.6% | | Sell | 0 firms | 0% | **Target Price:** $185 ~ $185 (Median $185) **vs Current Price:** about **74.1% upside** **Insider Activity:** Net selling in past 3 months > There were multiple insider sales in May 2026, including by CEO William Lewis and other executives. Some of these transactions were tied to option exercises (`M`) plus sales (`S`), so this is not automatically a red flag—but when a stock is under pressure, insider selling rarely helps sentiment. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Launch Execution Risk:** BRINSUPRI is now the core growth engine, but concerns around discontinuation rates have already surfaced → If uptake quality weakens, revenue expectations could reset lower quickly. 2. **Competition Risk:** Analysts have recently cited competitive pressures when cutting price targets → If rivals gain traction, Insmed may struggle to defend premium growth assumptions. 3. **Financing/Dilution Risk:** The company remains deeply unprofitable and has filed a mixed shelf offering → If cash burn stays high, shareholders could face dilution or more expensive financing. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Insmed is a commercial-stage biotech with one established product base and one major newer growth driver, so it's more advanced than a typical early-stage biotech. > > **Key strength:** The big plus is that revenue growth is real and backed by very high gross margins, which means the business could become very profitable if scale kicks in. > > **Key risk:** The main concern is that the valuation still assumes strong execution from BRINSUPRI and the pipeline, while current earnings, cash flow, and recent sentiment do not leave much room for operational disappointment. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis